First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

Impact · against what's priced in

Takeda's VERDICT trial provides a clinical basis for a new 'treat-to-target' standard in ulcerative colitis, potentially increasing drug adherence and expanding the addressable market for ENTYVIO. This data creates a structural growth catalyst by demonstrating a 70% reduction in disease-related complications when targeting disease clearance over symptomatic remission.

4502+0.60: No priced-in read yet

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

What matters in this story

Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

What matters in this story

Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.

How each ticker is affected

Track these names every morning.

This Biotech Stock Sinks Below $1 After Key Eye Drug Fails and Staff Is Slashed. Why There's Still Hope.

What a Mixed Midterm Result Could Mean for These 2 Health Care ETFs

BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026

Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

What matters in this story

Next reads from the same story arc

Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

What matters in this story

Next reads from the same story arc

Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.

How each ticker is affected

Track these names every morning.

This Biotech Stock Sinks Below $1 After Key Eye Drug Fails and Staff Is Slashed. Why There's Still Hope.

What a Mixed Midterm Result Could Mean for These 2 Health Care ETFs

BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026

Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site